Combining Dinutuximab with ALT-803 (IL-15 Superagonist) Significantly Improves the Activity of Ex Vivo Expanded Natural Killer Cells Against GD2+ Pediatric Solid Tumors (ST)
Author Type(s)
Faculty, Student, Resident/Fellow
Document Type
Abstract
Publication Date
3-2018
Journal Title
Biology of Blood and Marrow Transplantation
Department
Pediatrics
Second Department
Health Behavior and Community Health
Recommended Citation
Nayyar, G., Chu, Y., Su, N., Rosenblum, J., Wong, H. C., Lee, D., & Cairo, M. S. (2018). Combining Dinutuximab with ALT-803 (IL-15 Superagonist) Significantly Improves the Activity of Ex Vivo Expanded Natural Killer Cells Against GD2+ Pediatric Solid Tumors (ST). Biology of Blood and Marrow Transplantation, 24 (3 Suppl.1), S420-S421. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/376
COinS
